Please ensure Javascript is enabled for purposes of website accessibility
Search
Accessibility Menu
Sellas Life Sciences Group Stock Quote

Sellas Life Sciences Group (NASDAQ: SLS)

$1.46
(-0.7%)
-$0.01
Price as of May 17, 2024, 4:00 p.m. ET

Sellas Life Sciences Group Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
SLS -14.12% -96.35% -48.39% -100%
S&P +26.33% +85.46% +13.13% +97%

Sellas Life Sciences Group Company Info

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.